Oberweis Asset Management Inc. Buys 169,600 Shares of MannKind Co. (NASDAQ:MNKD)

Oberweis Asset Management Inc. grew its position in MannKind Co. (NASDAQ:MNKD - Free Report) by 21.2% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 968,400 shares of the biopharmaceutical company's stock after purchasing an additional 169,600 shares during the period. Oberweis Asset Management Inc. owned about 0.35% of MannKind worth $6,227,000 at the end of the most recent reporting period.

Other large investors also recently made changes to their positions in the company. Barclays PLC boosted its position in MannKind by 186.0% in the third quarter. Barclays PLC now owns 519,865 shares of the biopharmaceutical company's stock worth $3,271,000 after purchasing an additional 338,121 shares during the last quarter. Principal Financial Group Inc. boosted its stake in MannKind by 401.8% in the third quarter. Principal Financial Group Inc. now owns 168,518 shares of the biopharmaceutical company's stock valued at $1,060,000 after acquiring an additional 134,937 shares during the last quarter. Victory Capital Management Inc. grew its position in shares of MannKind by 358.6% during the 4th quarter. Victory Capital Management Inc. now owns 219,367 shares of the biopharmaceutical company's stock valued at $1,411,000 after acquiring an additional 171,537 shares during the period. Arrowstreet Capital Limited Partnership grew its holdings in MannKind by 275.9% during the fourth quarter. Arrowstreet Capital Limited Partnership now owns 4,887,609 shares of the biopharmaceutical company's stock valued at $31,427,000 after purchasing an additional 3,587,484 shares during the period. Finally, Charles Schwab Investment Management Inc. increased its position in MannKind by 2.0% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 2,270,106 shares of the biopharmaceutical company's stock worth $14,597,000 after buying an additional 45,277 shares during the last quarter. 49.55% of the stock is owned by institutional investors.

MannKind Trading Up 1.2 %

Shares of MannKind stock traded up $0.06 on Wednesday, hitting $4.97. 693,074 shares of the company traded hands, compared to its average volume of 2,385,700. The company has a market cap of $1.51 billion, a P/E ratio of 71.00 and a beta of 1.22. MannKind Co. has a 12-month low of $4.11 and a 12-month high of $7.63. The firm's 50-day simple moving average is $4.98 and its 200 day simple moving average is $5.92.

MannKind (NASDAQ:MNKD - Get Free Report) last announced its quarterly earnings data on Wednesday, February 26th. The biopharmaceutical company reported $0.03 EPS for the quarter, meeting the consensus estimate of $0.03. The firm had revenue of $76.78 million for the quarter, compared to analyst estimates of $74.99 million. MannKind had a negative return on equity of 17.74% and a net margin of 8.07%. Analysts predict that MannKind Co. will post 0.1 earnings per share for the current year.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on MNKD. StockNews.com upgraded MannKind from a "hold" rating to a "buy" rating in a research note on Wednesday, March 19th. Wedbush reaffirmed an "outperform" rating and issued a $11.00 price target on shares of MannKind in a report on Thursday, February 27th. Finally, Mizuho assumed coverage on MannKind in a research note on Thursday, April 10th. They set an "outperform" rating and a $12.00 price objective on the stock. Eight research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of "Buy" and a consensus target price of $9.56.

MannKind Profile

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults.